Direct to Consumer Test Marketing is Successful
Ikigai Holdings, LLC is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Ikigai developed the “POOPH” brand, created television commercials and other advertising content, and then conducted a television direct-response test marketing campaign to assess the probability that the product would be a commercial success.
BioLargo CEO Dennis P. Calvert commented, “Ikigai will purchase the POOPH products from us, and in addition, we receive a royalty on sales. They will finance and manage product roll-out, distribution, and marketing. We are excited about the potential for this partnership to create significant new revenue for both partners. The team at Ikigai is amazing!”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and
commercializes innovative platform technologies to solve challenging
environmental problems like PFAS contamination, advanced water and wastewater
treatment, industrial odor and VOC control, air quality control, and infection
control. With over 13 years of extensive R&D, BioLargo holds a wide array
of issued patents, maintains a robust pipeline of products, and provides
full-service environmental engineering. Our peer-reviewed scientific approach
allows us to invent or acquire novel technologies and develop them to maturity
through our operating subsidiaries. With a keen emphasis on collaborations with
academic, municipal, and commercial organizations and associations, BioLargo
has proven itself with over 80 awarded grants and numerous pilot projects. We
monetize through direct sales, recurring service contracts, licensing
agreements, strategic joint venture formation and/or the sale of the IP. See
our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19
pandemic; anticipated revenue; and plans for future operations. These
statements involve risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation: the effect of
the COVID-19 pandemic on the Company’s business, results of operations,
financial condition, and stock price; the effect of regional economic
conditions on the Company’s business, including effects on purchasing decisions
by consumers and businesses; the ability of the Company to compete in markets
that are highly competitive and subject to rapid technological change; the
ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological innovations on a
timely basis; the dependency of the Company on the performance of distributors
of the Company’s products. More information on these risks and other potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
